Impel Neuropharma Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Impel Neuropharma are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Impel Neuropharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Impel Neuropharma is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
Impel |
Impel Neuropharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Impel Neuropharma on September 30, 2025 and sell it today you would earn a total of 100.00 from holding Impel Neuropharma or generate -100.0% return on investment over 90 days. Impel Neuropharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Impel, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Impel Neuropharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Impel Neuropharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Impel Neuropharma, and traders can use it to determine the average amount a Impel Neuropharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IMPL |
Based on monthly moving average Impel Neuropharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Impel Neuropharma by adding Impel Neuropharma to a well-diversified portfolio.
Impel Neuropharma Fundamentals Growth
Impel Stock prices reflect investors' perceptions of the future prospects and financial health of Impel Neuropharma, and Impel Neuropharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Impel Stock performance.
| Return On Equity | -25.46 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (2.55) % | |||
| Current Valuation | 115.52 M | |||
| Shares Outstanding | 23.9 M | |||
| Price To Book | 18.46 X | |||
| Price To Sales | 0.05 X | |||
| Revenue | 20.99 M | |||
| EBITDA | (68.96 M) | |||
| Cash And Equivalents | 97.83 M | |||
| Cash Per Share | 4.12 X | |||
| Total Debt | 51.19 M | |||
| Book Value Per Share | (3.87) X | |||
| Cash Flow From Operations | (79.09 M) | |||
| Earnings Per Share | (3.12) X | |||
| Total Asset | 88.55 M | |||
| Retained Earnings | (321.11 M) | |||
Things to note about Impel Neuropharma performance evaluation
Checking the ongoing alerts about Impel Neuropharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Impel Neuropharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Impel Neuropharma is not yet fully synchronised with the market data | |
| Impel Neuropharma has some characteristics of a very speculative penny stock | |
| Impel Neuropharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 20.99 M. Net Loss for the year was (74.28 M) with profit before overhead, payroll, taxes, and interest of 6.16 M. | |
| Impel Neuropharma currently holds about 97.83 M in cash with (79.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.12. | |
| Roughly 72.0% of the company shares are owned by institutional investors |
- Analyzing Impel Neuropharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Impel Neuropharma's stock is overvalued or undervalued compared to its peers.
- Examining Impel Neuropharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Impel Neuropharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Impel Neuropharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Impel Neuropharma's stock. These opinions can provide insight into Impel Neuropharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Impel Stock
If you are still planning to invest in Impel Neuropharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Impel Neuropharma's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |